News on ICON Clinical Research Ltd from BioPortfolio.com http://www.BioPortfolio.com Consolidated ICON Clinical Research Ltd news from BioPortfolio.com Wed, 10 Feb 2010 02:24:47 GMT en XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039316&HITNO=0&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039316&THISHREF=http://c.moreover.com/click/here.pl%3fz2538020148%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039316&HITNO=0&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039316&THISHREF=http://c.moreover.com/click/here.pl%3fz2538020148%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comXOMA: BiomedReports: News and FDA Updates for PPD (Nasdaq:PPDI), Repros Therapeutics (Nasdaq:RPRX), Stem Cell Theraphttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039165&HITNO=1&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039165&THISHREF=http://c.moreover.com/click/here.pl%3fz2537964625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039165&HITNO=1&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039165&THISHREF=http://c.moreover.com/click/here.pl%3fz2537964625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comQuote.com Japan: Raise Your Hand In Support Of Millions Of Americans Affected By Rare Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039078&HITNO=2&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039078&THISHREF=http://c.moreover.com/click/here.pl%3fz2537909287%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039078&HITNO=2&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039078&THISHREF=http://c.moreover.com/click/here.pl%3fz2537909287%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: ICON promotes Tom OLearyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034126&HITNO=3&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034126&THISHREF=http://c.moreover.com/click/here.pl%3fz2535647177%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034126&HITNO=3&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034126&THISHREF=http://c.moreover.com/click/here.pl%3fz2535647177%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: ICON names Tom O'Leary president, Central Laboratorieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038180&HITNO=4&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038180&THISHREF=http://c.moreover.com/click/here.pl%3fz2537520624%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038180&HITNO=4&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038180&THISHREF=http://c.moreover.com/click/here.pl%3fz2537520624%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Research and Markets: Neurology: A Queen Square Textbookhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032668&HITNO=5&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032668&THISHREF=http://c.moreover.com/click/here.pl%3fz2534758432%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032668&HITNO=5&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032668&THISHREF=http://c.moreover.com/click/here.pl%3fz2534758432%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: SMT Research and Development, Ltd. Reports Two Successful Clinical Caseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038521&HITNO=6&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038521&THISHREF=http://c.moreover.com/click/here.pl%3fz2537643574%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038521&HITNO=6&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038521&THISHREF=http://c.moreover.com/click/here.pl%3fz2537643574%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMontana's News Station: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=7&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=7&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInterest!ALERT: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=8&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=8&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: SMT Research and Development, Ltd. Reports Two Successful Clinical Caseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034928&HITNO=9&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034928&THISHREF=http://c.moreover.com/click/here.pl%3fz2536051835%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034928&HITNO=9&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034928&THISHREF=http://c.moreover.com/click/here.pl%3fz2536051835%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comKLFY: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=10&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=10&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=11&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=11&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=12&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=12&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDMN Newswire: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=13&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=13&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGlobeNewswire via MSN Money: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=14&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=14&MSIZE=235&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ICON%20Clinical%20Research%20Ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: